Research Field
- Outside the AIT Research Fields
- Former Research Field - Digital Safety and Security
Myeloblative Therapy (MAT) and Immunotherapy (IT) with ch14.18/CHO for High Risk Neuroblastoma: Update and News of Randomised Results from the HR-NBL1/SIOPEN Trial
- Ruth Ladenstein (Speaker)
- Schreier, G. (Author)
Activity: Talk or presentation / Lecture › Presentation at a scientific conference / workshop